Since early last March, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to the Covid-19 pandemic. Many companies have delayed the initiation of planned trials or withdrawn them completely, while others have suspended enrollment in their ongoing trials or terminated the trials altogether. The majority of trial disruptions can be attributed to patient safety measures, strict lockdown requirements, social distancing procedures and the high demand on medical professionals to treat Covid-19 patients.
As the initial peak of the virus started declining, many trials were set to resume activity, but the number of confirmed Covid-19 cases is now increasing again due to the emergence of new variants.
The Covid-19 Dashboard on GlobalData’s Pharma Intelligence Centre dynamically tracks both disrupted and resumed trials.
As of 17 September, the number of resumed trials stands at 1,095. Out of these trials, 51.6% are currently recruiting participants, while 22.6% have completed recruitment but are still ongoing, but are yet to start recruiting subjects. The figure below shows that the number of trials resuming has increased slightly, even though the trend is very gradual. This slow increase is mainly due to the rise of global Covid-19 cases, especially the Delta variant. Sponsors are continuing to focus on moving to decentralised or virtual trials to overcome lockdown measures.
The US has the highest proportion of resumed trials at 69.1%, followed by the UK at 9.4%, Spain at 7.5%, France at 7.3% and Germany at 6.7%.